bioMerieux SA (BIM)-医療機器分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8012946)
◆英語タイトル:bioMerieux SA (BIM) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8012946
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
bioMerieux S.A. (bioMerieux) designs, develops and manufactures diagnostic systems and reagents for physicians and biologists. The company offers diagnostic solutions such as instruments, reagents and software. bioMerieux products are used diagnosing and managing infectious diseases, cardiovascular diseases and targeted cancers. The company also provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for agri-food, cosmetics and pharmaceutical industries. The company conducts its operations through subsidiaries and a broad network of distributors. bioMerieux is a part of the Institut Merieux group and is headquartered in Marcy l’Etoile, France.

bioMerieux SA (BIM) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
bioMerieux SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
bioMerieux SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
bioMerieux SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
bioMerieux SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
bioMerieux SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
bioMerieux SA, Medical Equipment, Deal Details 12
Venture Financing 12
Quanterix Raises US$19 Million In Series C Financing 12
Private Equity 14
BioTheranostics Raises USD32 Million in Private Equity Financing 14
Athyrium Opportunities Fund Invests US$20 Million In BioFire Diagnostics 15
Partnerships 16
Quanterix Enters into Licensing Agreement with bioMerieux 16
BioMerieux Enters into Licensing Agreement with Astute Medical 17
Seegene Enters Into Licensing Agreement With BioMerieux For DPO And TOCE Technologies 18
Lonza Walkersville Enters Into Licensing Agreement With Hyglos For Endotoxin Detection Patents 19
bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 20
Biomerieux Enters into Agreement with Banyan Biomarkers 21
ITL Biomedical Enters into Distribution Agreement with bioMerieux Canada 22
Biotheranostics Enters into Agreement with Syapse 23
BioMerieux Enters into Co-Development Agreement with Copan Italia 24
BioMerieux Enters into Distribution Agreement with Copan 25
BioMerieux Enters into Distribution Agreement with Copan for WASP and WASPLab 26
BioMerieux Enters into Co-Development Agreement with Illumina 27
PathoGenetix And Applied Maths Enter Into Technology Integration Agreement For Pathogen Strain Typing 28
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 29
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 30
Debt Offering 31
bioMerieux Completes Private Placement Of Bonds Due 2020 For US$406.6 Million 31
Acquisition 32
bioMerieux to Acquire 34% Stake in Sysmex bioMerieux from Sysmex 32
BioMerieux Acquires Applied Maths 33
BioMerieux Completes Acquisition Of BioFire Diagnostics For US$486 Million 34
Biosynex Acquires Dima Gesellschaft Fur Diagnostika, Rapid Diagnostic Tests Maker 36
bioMerieux Completes Acquisition Of AES Laboratoire 37
bioMerieux Acquires Argene 39
bioMerieux SA – Key Competitors 40
bioMerieux SA – Key Employees 41
bioMerieux SA – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 48
Financial Announcements 48
Aug 30, 2017: bioMerieux – First-Half 2017 Results 48
Jul 20, 2017: bioMerieux – Second-Quarter 2017 Business Review 51
Apr 20, 2017: bioMerieux – First-Quarter 2017 Business Review 53
Mar 01, 2017: bioMerieux – 2016 Financial Results 56
Jan 19, 2017: bioMerieux – Fourth-Quarter 2016 Business Review 59
Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016 61
Aug 31, 2016: bioMerieux – First-Half 2016 Results 64
Jul 18, 2016: bioMerieux – Second-Quarter 2016 Business Review 68
Apr 20, 2016: bioMérieux – First-Quarter 2016 Business Review 71
Mar 02, 2016: bioMerieux – 2015 Financial Results 73
Jan 21, 2016: bioMerieux – Fourth-Quarter 2015 Business Review 77
Corporate Communications 80
Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux 80
Product News 81
Jan 05, 2017: Quanterix to Present at The 35th Annual J.P. Morgan Healthcare Conference 81
Oct 10, 2016: bioMerieux: Lyme disease diagnostic tests 82
Oct 06, 2016: bioMerieux introduces EviSight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical productio 83
Jul 06, 2016: bioMerieux enlarges its pathogen identification capability on VITEK MS 84
Other Significant Developments 85
Oct 18, 2017: bioMerieux – Business review for the nine months ended September 30, 2017 85
Oct 10, 2016: BIOASTER, bioMerieux, ESPCI, GSK, Hospices Civils de Lyon and Sanofi join forces against sepsis 87
Aug 08, 2016: ITL contract extended with bioMerieux 89
May 31, 2016: bioMerieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 90
Mar 22, 2016: bioMérieux and COPAN announce the first commercial success of their collaboration for the automation and efficiency of microbiology laboratories 91
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92

List of Tables
bioMerieux SA, Medical Equipment, Key Facts, 2016 2
bioMerieux SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
bioMerieux SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
bioMerieux SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
bioMerieux SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
bioMerieux SA, Deals By Market, 2011 to YTD 2017 9
bioMerieux SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Quanterix Raises US$19 Million In Series C Financing 12
BioTheranostics Raises USD32 Million in Private Equity Financing 14
Athyrium Opportunities Fund Invests US$20 Million In BioFire Diagnostics 15
Quanterix Enters into Licensing Agreement with bioMerieux 16
BioMerieux Enters into Licensing Agreement with Astute Medical 17
Seegene Enters Into Licensing Agreement With BioMerieux For DPO And TOCE Technologies 18
Lonza Walkersville Enters Into Licensing Agreement With Hyglos For Endotoxin Detection Patents 19
bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 20
Biomerieux Enters into Agreement with Banyan Biomarkers 21
ITL Biomedical Enters into Distribution Agreement with bioMerieux Canada 22
Biotheranostics Enters into Agreement with Syapse 23
BioMerieux Enters into Co-Development Agreement with Copan Italia 24
BioMerieux Enters into Distribution Agreement with Copan 25
BioMerieux Enters into Distribution Agreement with Copan for WASP and WASPLab 26
BioMerieux Enters into Co-Development Agreement with Illumina 27
PathoGenetix And Applied Maths Enter Into Technology Integration Agreement For Pathogen Strain Typing 28
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 29
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 30
bioMerieux Completes Private Placement Of Bonds Due 2020 For US$406.6 Million 31
bioMerieux to Acquire 34% Stake in Sysmex bioMerieux from Sysmex 32
BioMerieux Acquires Applied Maths 33
BioMerieux Completes Acquisition Of BioFire Diagnostics For US$486 Million 34
Biosynex Acquires Dima Gesellschaft Fur Diagnostika, Rapid Diagnostic Tests Maker 36
bioMerieux Completes Acquisition Of AES Laboratoire 37
bioMerieux Acquires Argene 39
bioMerieux SA, Key Competitors 40
bioMerieux SA, Key Employees 41
bioMerieux SA, Other Locations 43
bioMerieux SA, Subsidiaries 43

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ bioMerieux SA (BIM)-医療機器分野:企業M&A・提携分析(bioMerieux SA (BIM) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆